Industry News
Pharmaceutical Industry News
Haleon has completed a hat-trick…
Haleon has completed a hat-trick of recent soccer initiatives, inking a pain management partnership with the organization responsible for protecting the health and safety of players in Europe.
Patients arrive informed….
Patients arrive informed. Marketers must shift from visibility to usefulness to earn trust.
A new survey undertaken by the…
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for certain bladder cancer patients are causing a major long-term emotional impact.
Shortly after locking down its…
Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough
The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.
Marty Makary, M.D., is resigning…
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting criticism from all sides, according to reports.
Eli Lilly has paused an obesity…
Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules for prescription medicines, Reuters reports.
Alkermes has chalked up a quick…
Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate drug Lumryz met all primary and key secondary endpoints
The deal includes up to $320…
The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer.
After staving off significant…
After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.
Amid apparent overtures from the…
Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the secretary of the Department of Health and Human Services is allegedly continuing his crusade in the
After positive momentum on the…
After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a new framework for the bloc focused on boosting supplies of critical medicines and navigating potential
As Bicara Therapeutics lines up…
As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer.
Colombians Are Fighting Over the Fate of Escobar’s Hippos
Colombia is facing pushback over its plan to cull wild hippos, which are descendants of the drug kingpin Pablo Escobar’s personal pets. The hippos, which are native to Africa, have threatened local wildlife and human
Supreme Court Continues Access to Abortion Pill by Mail, for a Few Days
Justice Samuel A. Alito Jr. has paused until at least Thursday a federal appeals court ruling against the Food and Drug Administration that would restrict access by mail to mifepristone.
CSL has slashed its revenue…
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion.
With the program’s seventh…
With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.
Daiichi Sankyo aims to transform…
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five
OVID Health has hired former…
OVID Health has hired former Edelman global public health lead Davide Scalenghe to expand the agency’s international strategy and partnerships work.
Flashy three-pointers; top…
Flashy three-pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli